Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: A meta-analysis and meta-regression

Rheumatology

Volumn 48, Issue 8, 2009, Pages 944-952

  Mak, Anselm ^a,c   Cheak, Alicia A C ^a   Tan, Jason Y S ^a   Su, Hnin Cho ^a   Ho, Roger C M ^a   Lau, Chak Sing ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Cyclophosphamide; Lupus; Meta analysis; Meta regression; Mycophenolate; Nephritis

Indexed keywords

CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

AMENORRHEA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HERPES SIMPLEX; HUMAN; KIDNEY FAILURE; LEUKOPENIA; LUPUS ERYTHEMATOSUS NEPHRITIS; META ANALYSIS; MORTALITY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SURVIVAL RATE; SYSTEMATIC REVIEW; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; REGRESSION ANALYSIS; TREATMENT OUTCOME;

CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; LUPUS NEPHRITIS; MYCOPHENOLIC ACID; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 70149115258     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep120     Document Type: Article

References (50)

1. Boumpas DT, Sidiropoulos P, Bertsias G. Optimum therapeutic approaches for lupus nephritis: what therapy and for whom? Nat Clin Pract Rheumatol 2005;1:22-30.
2. Mak A, Mok CC, Chu WP et al. Renal damage in systemic lupus erythematosus: a comparative analysis of different age groups. Lupus 2007;16:28-34.
3. Mok CC, Wong RW, Lai KN. Treatment of severe proliferative lupus nephritis: the current state. Ann Rheum Dis 2003;62:799-804.
4. Austin HA 3rd, Klippel JH, Balow JE et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-9.
5. Buhaescu I, Covic A, Deray G. Treatment of proliferative lupus nephritis-a critical approach. Semin Arthritis Rheum 2007;36:224-37.
6. Illei GG, Takada K, Parkin D et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term follow-up of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002;46:995-1002.
7. Mok CC, Ying KY, Tang S et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulo-nephritis. Arthritis Rheum 2004;50:2559-68.
8. Valeri A, Radhakrishnan J, Estes D et al. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study. Clin Nephrol 1994;42:71-8.
9. Mok CC, Ho CTK, Siu YP et al. Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens. Am J Kidney Dis 2001;38:256-64.
10. Mok CC, Mak A, To CH. Mycophenolate mofetil for lupus related myelopathy. Ann Rheum Dis 2006;65:971-3.
11. Mak A, Mok CC. Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus. Lupus 2005;14:856-8.
12. Moder KG, Amin S, Mazlumzadeh M et al. The effect of mycophenolate mofetil on patients with active non-renal SLE. Clin Exp Rheumatol 2007;25:932.
13. Schanz S, Ulmer A, Rassner G et al. Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. Br J Dermatol 2002;147:174-8.
14. Pisoni CN, Karim Y, Cuadrado MJ. Mycophenolate mofetil and systemic lupus erythematosus: an overview. Lupus 2005;14(Suppl. 1):S9-11.
15. Chan TM, Li FK, Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000;343:1156-62.
16. Hu W, Liu Z, Chen H et al. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin Med J 2002;115:705-9.
17. Contreras G, Pardo V, Leclercq B et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971-80.
18. Ong LM, Hooi LS, Lim TO et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology 2005;10:504-10.
19. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219-28.
20. Chan TM, Tse KC, Tang CS et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005;16:1076-84.
21. Wang J, Hu W, Xie H et al. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide. Lupus 2007;16:707-12.
22. Flores-Suarez LF, Villa AR. Preliminary results of an open label randomized clinical trial comparing mycophenolate mofetil (MMF) vs intravenous cyclophosphamide as induction therapy for severe lupus nephritis. Arthritis Rheum 2004;50(Suppl. 1):S1029.
23. Isenberg D, Appel G, Dooley MA et al. Mycophenolate mofetil compared with intravenous cyclophosphamide as induction for lupus nephritis. Ann Rheum Dis 2008;67(Suppl. II):S53.
24. Mulic-Bacic S, Antic D, Krizic M et al. Mycophenolate mofetil or intravenous cyclophosphamide in treatment of lupus nephritis. Ann Rheum Dis 2008;67 (Suppl. II):S349.
25. Ye Z, Tan YH, Hong XP et al. MMF vs CTX in the treatment of severe SLE patients. Lupus 2001;10(Suppl. 1):S99.
26. Walsh M, James M, Jayne D et al. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2007;2:968-75.
27. Zhu B, Chen N, Lin Y et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2007;22:1933-42.
28. Moore RA, Derry S. Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Ther 2006;8:R182.
29. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
30. Cochrane Handbook for Systematic Reviews of Interventions. http://www.cochranehandbook.org/ [18 March, 2009, date last accessed]
31. Hardy RJ, Thompson SG. Detecting and describing heterogeneity in meta-analysis. Stat Med 1998;17:841-56.
32. Fletcher J. What is heterogeneity and is it important? Br Med J 2007;334:94-6.
33. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
34. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002;21:1559-73.
35. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000;53:1119-29.
36. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 1999;354:1896-900.
37. Fleiss JL. Measuring nominal scale agreement among many raters. Psychol Bull 1971;76:378-82.
38. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
39. Glicklich D, Acharya A. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am J Kidney Dis 1998;32:318-22.
40. Dooley MA, Cosio FG, Nachman PH et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 1999;10:833-9.
41. Sesso R, Monteiro M, Sato E et al. A controlled trial of pulse cyclophosphamide versus pulse methylprednisolone in severe lupus nephritis. Lupus 1994;3:107-12.
42. Belmont HM, Storch M, Buyon J et al. New York University/Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: efficacy in steroid unresponsive lupus nephritis. Lupus 1995;4:104-8.
43. Dooley MA, Ginzler EM. Newer therapeutic approaches for systemic lupus erythematosus: immunosuppressive agents. Rheum Dis Clin North Am 2006;32: 91-102.
44. Korbet SM, Schwartz MM, Evans J. Lewis EJ; Collaborative Study Group. Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol 2007;18:244-54.
45. Illei GG, Takada K, Parkin D et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002;46:995-1002.
46. Ginzler EM, Appel GB, Dooley MA et al. Mycophenolate mofetil and intravenous cyclophosphamide in the Aspreva Lupus Management Study (ALMS): efficacy by racial group. Arthritis Rheum 2007;56:4308.
47. Bouali H, Nietert P, Nowling TM et al. Association of the G-463A myeloperoxidase gene polymorphism with renal disease in African Americans with systemic lupus erythematosus. J Rheumatol 2007;34:2028-34.
48. Rovin BH, Lu L, Zhang X. A novel interleukin-8 polymorphism is associated with severe systemic lupus erythematosus nephritis. Kidney Int 2002;62:261-5.
49. Morgenstern H. Uses of ecological analysis in epidemiologic research. Am J Public Health 1982;72:127-30.
50. Houssiau FA, Vasconcelos C, D'Cruz D et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121-31.